Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2

Journal of the National Cancer Institute

Volumn 105, Issue 6, 2013, Pages 378-379

  Cogle, Christopher R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON HELPER INTEGRATION SITE 1; ABELSON KINASE; ALPHA INTERFERON; BCR ABL PROTEIN; CD135 ANTIGEN; IMATINIB; INTERLEUKIN 6; JANUS KINASE 2; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; N TERT BUTYL 3 [5 METHYL 2 [4 (4 METHYL 1 PIPERAZINYL)PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PROTEIN RET; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLELE; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; ENZYME INHIBITION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIMIT OF DETECTION; MOLECULAR CLONING; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SHORT SURVEY; STEM CELL; TUMOR MICROENVIRONMENT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICROFILAMENT PROTEINS; NEOPLASTIC STEM CELLS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84875576046     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt029     Document Type: Short Survey

References (9)

1. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101(12):4701-4707.
2. Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
3. Chen M, Gallipoli, P, DeGeer D, et al. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABLJAK2 complex. J Natl Cancer Inst. 2013;105(6):405-423.
4. Jiang X, Zhao Y, Chan WY, et al. Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia. Blood. 2004;103(10):3897-3904.
5. Zhou LL, Zhao Y, Ringrose A, et al. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. J Exp Med. 2008;205(11):2657-2671.
6. Samanta A, Perazzona B, Chakraborty S, et al. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia. 2011;25(3): 463-472.
7. Traer E, MacKenzie R, Snead J, et al. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia. 2012;26(5):1140-1143.
8. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2- selective kinase inhibitor potently inhibits myeloproliferative disorder- associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007;21(8):1658-1668.
9. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.